Ren Dong, Lin Bihua, Zhang Xin, Peng Yao, Ye Ziyu, Ma Yan, Liang Yangfang, Cao Longbin, Li Xiangyong, Li Ronggang, Sun Lixia, Liu Qiongru, Wu Jinhua, Zhou Keyuan, Zeng Jincheng
Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Key Laboratory of Medical Bioactive Molecular Research for Department of Education of Guangdong Province, Guangdong Medical University, Dongguan, Guangdong Province, 523808, China.
Department of Orthopedic Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, 510080, China.
Oncotarget. 2017 Jul 25;8(30):49807-49823. doi: 10.18632/oncotarget.17971.
Emerging studies indicated that cancer stem cells represent a subpopulation of cells within the tumor that is responsible for chemotherapeutic resistance. However, the underlying mechanism is still not clarified yet. Here we report that miR-196b-5p is dramatically upregulated in CRC tissues and high expression of miR-196b-5p correlates with poor survival in CRC patients. Moreover, recurrent gains (amplification) contribute to the miR-196b-5p overexpression in CRC tissues. Silencing miR-196b-5p suppresses spheroids formation ability, the fraction of SP cells, expression of stem cell factors and the mitochondrial potential, and enhances the apoptosis induced by 5-fluorouracil in CRC cells; while ectopic expression of miR-196b-5p yields an opposite effect. In addition, downregulation of miR-196b-5p resensitizes CRC cells to 5-fluorouracil in vivo. Our results further demonstrate that miR-196b-5p promotes stemness and chemoresistance of CRC cells to 5-fluorouracil via targeting negative regulators SOCS1 and SOCS3 of STAT3 signaling pathway, giving rise to activation of STAT3 signaling. Interestingly, miR-196b-5p is highly enriched in the serum exosomes of patients with CRC compared to the healthy control subjects. Thus, our results unravel a novel mechanism of miR-196b-5p implicating in the maintenance of stem cell property and chemotherapeutic resistance in CRC, offering a potential rational registry of anti-miR-196b-5p combining with conventional chemotherapy against CRC.
新兴研究表明,癌症干细胞是肿瘤内的一个细胞亚群,负责化疗耐药性。然而,其潜在机制仍未阐明。在此我们报告,miR-196b-5p在结直肠癌组织中显著上调,且miR-196b-5p的高表达与结直肠癌患者的不良生存相关。此外,反复获得(扩增)导致结直肠癌组织中miR-196b-5p过表达。沉默miR-196b-5p可抑制球体形成能力、侧群细胞比例、干细胞因子表达和线粒体电位,并增强5-氟尿嘧啶诱导的结直肠癌细胞凋亡;而miR-196b-5p的异位表达则产生相反的效果。此外,下调miR-196b-5p可使结直肠癌细胞在体内对5-氟尿嘧啶重新敏感。我们的结果进一步证明,miR-196b-5p通过靶向STAT3信号通路的负调节因子SOCS1和SOCS3促进结直肠癌细胞的干性和对5-氟尿嘧啶的化疗耐药性,从而导致STAT3信号通路激活。有趣的是,与健康对照受试者相比,miR-196b-5p在结直肠癌患者的血清外泌体中高度富集。因此,我们的结果揭示了miR-196b-5p参与维持结直肠癌干细胞特性和化疗耐药性的新机制,为抗miR-196b-5p与传统化疗联合治疗结直肠癌提供了潜在的合理依据。